Two mechanisms for platelet-mediated killing of tumour cells: One cyclo-oxygenase dependent and the other nitric oxide dependent

Immunology

Volumn 89, Issue 1, 1996, Pages 158-164

  Okada, M ^a   Sagawa, T ^a   Tominaga, A ^a   Kodama, T ^b   Hitsumoto, Y ^c  

^a EHIME PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE B2;

ARTICLE; CANCER CELL DESTRUCTION; CELL LINE; CYTOTOXICITY; ELECTRON MICROSCOPY; HUMAN; LUNG CANCER; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0029790897     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1996.d01-716.x     Document Type: Article

References (28)

1. SHIN H.S., HAYDES M., LANGLEY S., KALISS N. & SMITH M.R. (1975) Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngenic and allogenic hosts. J Immunol 114, 1255.
2. JOHNSON R.J., PASTERNACK G.R. & SHIN H.S. (1977) Antibody-mediated suppression of tumor growth. II. Macrophage and platelet cooperation with murine IgG1 isolated from alloantiserum. J Immunol 118, 494.
3. IBELE G.M., KAY N.E., JOHNSON G.J. & JACOB H.S. (1985) Human platelets exert cytotoxic effects on tumor cells. Blood 65, 1252.
4. SAGAWA T., KODAMA T., TOMINAGA A. & OKADA M. (1990) Human platelets effectively kill K-562 cells, a chronic myelogenic leukemia cell line, in vitro. Jap J Cancer Res 81, 449.
5. BYKOVSKAYA S.N., BOLVACHEVA A.V., KISELEVSKY M.V., KHAYLENKO V.A. & BYKOVSKY A.F. (1991) Platelet-mediated cytotoxicity and its enhancement by platelet activating factor. Biomed Pharmacother 45, 279.
6. SAGAWA T., TOMINAGA A., KODAMA T. & OKADA M. (1993) Cytotoxicity of unstimulated and thrombin-activated platelets to human tumour cells. Immunology 78, 650.
7. JOSEPH M., AURIAULT C., CAPRON A., VORNG H. & VIENS P. (1983) A new function for platelets: IgE-dependent killing of schistosomes. Nature 303, 810.
8. PANCRE V., CESBRON J.Y., AURIAULT C., JOSEPH M., CHANDENIER J. & CAPRON A. (1988) IgE-dependent killing of Brugia malayi microfilariae by human platelets and its modulation by T cell products. Int Arch Allergy Appl Immunol 85, 483.
9. YONG E.C., CHI E.Y., FRITSCHE T.R. & HENDERSON W.R. (1991) Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane. J Exp Med 173, 65.
10. OKADA M., KODAMA T., TOMINAGA A., KON K., SAGAWA T. & UTSUMI S. (1992) Cytotoxicity of activated platelets to autologous red blood cells. Br J Haematol 82, 142.
11. WIEDMER T. & SIM P.J. (1985) Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem 260, 8014.
12. HAMBERG M., SVENSSON J. & SAMUELSSON B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Natl Sci USA 72, 2994.
13. 2 and prostacyclin. Pharmacol Rev 30, 293.
14. 2 synthetase activity by sodium 5-(3′-pyridinylmethyl)benzofurane-2-carboxylate. Prostaglandins 26, 325.
15. BERTELE V., CERLETTI C., SCHIEPPATI A., DI MINNO G. & DE GAETANO G. (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1, 1057.
16. RADOMSKI M.W., PALMER R.M.J. & MONKADA S. (1990) Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 101, 325.
17. PRONAI L., ICHIMORI K., NOZAKI H. et al. (1991) Investigation of the existence and biological role of L-arginine/nitric oxide pathway in human platelets by spin-trapping/ESR studies. Eur J Biochem 202, 923.
18. MONCADA S., PALMER R.M.J. & HIGGS E.A. (1991) Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev 43, 109.
19. MALINSKI T., RADOMSKI M.W., TAHA Z. & MONCADA S. (1993) Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194, 960.
20. HIBBS J.B., TAINTOR R.R., VAVRIN Z. & RACHLIN E.M. (1988) Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157, 87.
21. STUEHR D.J. & NATHAN C.F. (1989) Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169, 1543.
22. HIGUCHI M., HIGASHI N., TAKI H. & OSAWA, T. (1990) Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J Immunol 144, 1425.
23. CUI S., REICHNER J.S., MATEO R.B. & ALBINA J.E. (1994) Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 54, 2462.
24. YAHN D.M. & FEINSTEIN M.B. (1981) Inhibition of platelet thromboxane synthetase by L-1-tosylamido-2-phenylethyl chloromethyl ketone. Prostaglandins 21, 243.
25. BREZINSKI M.E., LEFER D.J., BOWKER B. & LEFER A.M. (1987) Thromboxane induced red blood cell lysis. Prostaglandins 33, 75.
26. ANDERSSON L.C., NILSSON K. & GARNBERG, C.G. (1979) K562 - A human erythroleukemic cell line. Int J Cancer 23, 143.
27. ARCHER S. (1993) Measurement of nitric oxide in biological models. FASEB J 7, 349.
28. TANAKA T., AKIRA S., YOSHIDA K. et al. (1995) Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80, 353.